Zobrazeno 1 - 10
of 46
pro vyhledávání: '"W J, Hoskins"'
Autor:
D S, Chi, W J, Hoskins
Publikováno v:
Methods in molecular medicine. 39
In the United States, ovarian cancer is the fifth most common cause of female cancer death behind lung, breast, colorectal, and pancreatic cancers. It is estimated that 14,500 women in the United States will die of ovarian cancer in 1999 (1). Epithel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::89c671492d215073166c3b73913bff73
https://pubmed.ncbi.nlm.nih.gov/21340759
https://pubmed.ncbi.nlm.nih.gov/21340759
Publikováno v:
European journal of gynaecological oncology. 22(4)
To assess the benefit of a special elective gynecologic oncology program for Obstetrics and Gynecology (Ob/Gyn) residents.We reviewed our housestaff records from July 1992 to June 1998 and the National Residency Matching Program (NRMP) subspeciality
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::32622a8c146df391d5b3d85654a43ebe
https://pubmed.ncbi.nlm.nih.gov/11695806
https://pubmed.ncbi.nlm.nih.gov/11695806
Autor:
J, Boyd, Y, Sonoda, M G, Federici, F, Bogomolniy, E, Rhei, D L, Maresco, P E, Saigo, L A, Almadrones, R R, Barakat, C L, Brown, D S, Chi, J P, Curtin, E A, Poynor, W J, Hoskins
Publikováno v:
JAMA. 283(17)
Most hereditary ovarian cancers are associated with germline mutations in BRCA1 or BRCA2. Attempts to define the clinical significance of BRCA mutation status in ovarian cancer have produced conflicting results, especially regarding survival.To deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5d96382d8fc6b72919189d91e8e5e14d
https://pubmed.ncbi.nlm.nih.gov/10807385
https://pubmed.ncbi.nlm.nih.gov/10807385
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(4)
Preclinical studies have demonstrated a relationship between DNA mismatch repair (MMR) status and sensitivity to cisplatin and carboplatin. MMR-deficient cells are resistant to both drugs, and selection for cisplatin resistance in vitro is sometimes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::60e99db4f2dc1d724a9042a11b627000
https://pubmed.ncbi.nlm.nih.gov/10778972
https://pubmed.ncbi.nlm.nih.gov/10778972
Publikováno v:
Seminars in surgical oncology. 17(3)
Cancer of the uterine cervix is the seventh most common malignancy among women and the fifth most common cause of cancer mortality worldwide. In the United States, the use of the Papanicolaou (Pap) smear for screening has meant a significant decline
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c1bc5b36941a46115596fad75efe4f1c
https://pubmed.ncbi.nlm.nih.gov/10504663
https://pubmed.ncbi.nlm.nih.gov/10504663
Publikováno v:
Seminars in oncology. 25(3)
Ovarian cancer remains the number one cause of mortality in gynecologic malignancies and the fifth most common cause of death among all malignancies in women. Unfortunately, recent data confirm that only approximately 90% of "apparent" early ovarian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7584e6fb1095f28b6a81bb3baa882d9c
https://pubmed.ncbi.nlm.nih.gov/9633844
https://pubmed.ncbi.nlm.nih.gov/9633844
Autor:
C L, Finstad, K O, Lloyd, M G, Federici, C, Divgi, E, Venkatraman, R R, Barakat, R D, Finn, S M, Larson, W J, Hoskins, J L, Humm
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(8)
Our objective was to quantify the targeting of the monoclonal antibody (mAb) MX35 F(ab')2 to micrometastatic epithelial ovarian cancer. This mAb detects a Mr 95,000 glycoprotein with homogeneous distribution on 80% of ovarian tumor specimens. Six pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8993c92ef580db4c431a05dbcd95ff32
https://pubmed.ncbi.nlm.nih.gov/9815829
https://pubmed.ncbi.nlm.nih.gov/9815829
Autor:
W P, McGuire, W J, Hoskins, M F, Brady, P R, Kucera, E E, Partridge, K Y, Look, D L, Clarke-Pearson, M, Davidson
Publikováno v:
Seminars in oncology. 24(1 Suppl 2)
This prospective study compared the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and cisplatin with the standard therapy of cyclophosphamide/cisplatin in women with suboptimal stage III and stage IV ovarian cancer. O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ffc1fdf8050547f10609b1f12b7e5371
https://pubmed.ncbi.nlm.nih.gov/9045329
https://pubmed.ncbi.nlm.nih.gov/9045329
Autor:
W P, McGuire, W J, Hoskins, M F, Brady, P R, Kucera, E E, Partridge, K Y, Look, D L, Clarke-Pearson, M, Davidson
Publikováno v:
Seminars in oncology. 23(5 Suppl 12)
Administration of an alkylating agent plus a platinum coordination complex is standard therapy for advanced epithelial ovarian cancer in the United States. The most commonly used combination is cyclophosphamide/ cisplatin; however, the benefit of thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::84031b06f91109f5e1175ae159701b63
https://pubmed.ncbi.nlm.nih.gov/8941409
https://pubmed.ncbi.nlm.nih.gov/8941409
Publikováno v:
The cancer journal from Scientific American. 2(1)
We conducted this retrospective study to determine the endometrial pathologic findings at the time of dilatation and curettage in breast cancer patients on tamoxifen and compare these findings with those from a similar group of patients not receiving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6e49862c81ff52e9d2c6dc0e3c97f2ce
https://pubmed.ncbi.nlm.nih.gov/9166496
https://pubmed.ncbi.nlm.nih.gov/9166496